Biotech entrepreneur Marco Quarta is developing targeted senolytic drugs designed to clear senescent “zombie” cells and target the root biology of aging. Operating from Silicon Valley through biotechnology firms like Rubedo Life Sciences, Quarta states that human clinical trials are advancing to test therapies aimed at extending healthspan rather than pursuing human immortality.
Targeting Senescent Cells to Combat Aging
As tissues age chronologically, certain cells transform into senescent states to protect the organism from immediate damage. According to Marco Quarta, a 50-year-old scientist and biotech entrepreneur based in California, these cells refuse to die and instead secrete toxins that fuel chronic systemic inflammation. This persistent inflammatory environment drives the onset of degenerative conditions such as Alzheimer’s, Parkinson’s, and various cancers as damaged cells accumulate over time.
To combat this cellular deterioration, Quarta and his team at Rubedo Life Sciences utilize artificial intelligence to identify distinct types of senescent cells hidden within tissues. Their research focuses on engineering smart pharmaceutical compounds that selectively eliminate these zombie cells from tissues. By targeting the fundamental drivers of biological aging, the therapeutics seek to prevent, slow, or even reverse degenerative disease trajectories before clinical symptoms manifest.
Clinical Trials and Therapeutic Applications
Rubedo Life Sciences has advanced its lead drug candidate into human clinical trials, focusing initial applications on localized tissue regeneration and skin pathologies. Clinical testing has demonstrated safety and efficacy in treating actinic keratosis—a precancerous skin lesion triggered by sun damage—as well as atopic dermatitis, psoriasis, and aged healthy skin.
Quarta notes that treating these conditions successfully reversed the biological age of the treated tissue in trials. Beyond dermatology, the biotechnology firm is preparing to launch another drug engineered to target internal organs. Once approved, these pharmaceutical interventions could eventually allow physicians to treat patients decades before diseases take root, using specific biological markers to detect early physiological shifts.
Bridging Silicon Valley Innovation with European Science
Born in Bolzano, Italy, Quarta earned a biotechnology degree in Bologna and a neuroscience doctorate in Padova before moving to Stanford University. Reflecting on his transition to the United States, Quarta emphasizes that while European academic training is exceptionally rigorous, Silicon Valley provides a unique ecosystem where venture capital swiftly translates academic discoveries into industrial applications through visionary risk-taking.
Despite his base in California, Quarta maintains active research ties with Europe, having established a Rubedo Life Sciences office in Milan to serve as a bridge to Silicon Valley innovation and conduct clinical trials. Commenting on extreme longevity trends popularized by figures like Bryan Johnson, Quarta advocates for disciplined, regulated scientific progression rather than unregulated personal experimentation, noting that rigorous clinical validation remains essential for developing safe therapeutics for the broader public.